Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis

Multiple Sclerosis

Volumn 16, Issue 1, 2010, Pages 68-77

  Patti, F ^a   Amato, Mp ^b   Bastianello, S ^c   Caniatti, L ^d   Di Monte, E ^e   Ferrazza, P ^f,g   Goretti, B ^b   Gallo, P ^h   Brescia Morra, V ⁱ   Lo Fermo, S ^a   Picconi, O ^j   Tola, Mr ^d   Trojano, M ^e  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^d UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f Opera CRO Scientific Advisor Board   (Italy)

^g IRCCS NEUROMED   (Italy)

^h UNIVERSITY HOSPITAL OF PADOVA   (Italy)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^j Public Health Agency of Lazio Region   (Italy)

more..

Author keywords

Cognitive function; Cognitive impairment; Disability; Disease progression; Interferon beta 1a; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL DISABILITY; PROGNOSIS;

ADOLESCENT; ADULT; COGNITION DISORDERS; COHORT STUDIES; DISABILITY EVALUATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 73949111235     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509350309     Document Type: Article

References (48)

1. Amato MP, Zipoli V., Portaccio E. Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. J Neurol Sci 2006 ; 245: 41-46.
2. Huijbregts SC, Kalkers NF, de Sonneville LM, de Groot V., Polman CH Cognitive impairment and decline in different MS subtypes. J Neurol Sci 2006 ; 245: 187-194.
3. Prakash RS, Snook EM, Lewis JM, Motl RW, Kramer AF Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis. Mult Scler 2008 ; 14: 1250-1261.
4. Haase CG, Tinnefeld M., Faustmann PM The influence of immunomodulation on psycho-neuroimmunological functions in benign multiple sclerosis. Neuroimmunomodulation 2004 ; 11: 365-372.
5. Glanz B., Holland C., Gauthier S., et al. Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Mult Scler 2007 ; 13: 1004-1010.
6. Feuillet L., Reuter F., Audoin B., et al. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2007 ; 13: 124-127.
7. Amato MP, Ponziani G., Siracusa G., Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 2001 ; 58: 1602-1606.
8. Lester K., Stepleman L., Hughes M. The association of illness severity, self-reported cognitive impairment, and perceived illness management with depression and anxiety in a multiple sclerosis clinic population. J Behav Med 2007 ; 30: 177-186.
9. Bagert B., Camplair P., Bourdette D. Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management. CNS Drugs 2002 ; 16: 445-455.
10. Rao SM, Leo GJ, Bernardin L., Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991 ; 41: 685-691.
11. Lynch SG, Parmenter BA, Denney DR The association between cognitive impairment and physical disability in multiple sclerosis. Mult Scler 2005 ; 11: 469-476.
12. Bobholz JA, Rao SM Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 2003 ; 16: 283-288.
13. Montalban X., Rio J. Interferons and cognition. J Neurol Sci 2006 ; 245: 137-140.
14. Patti F., Amato MP, Bastianello S., et al. Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsing- remitting multiple sclerosis: 2-year results from the COGIMUS study. Ther Adv Neurol Disorders 2009 ; 2: 67-77.
15. Patti F., Amato MP, Trojano M., et al. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Mult Scler 2009 ; 15: 779-788.
16. McDonald WI, Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 ; 50: 121-127
17. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 ; 33: 1444-1452.
18. Barbarotto R., Laiacona M., Frosio R., Vecchio M., Farinato A., Capitani E. A normative study on visual reaction times and two Stroop colour-word tests. Ital J Neurol Sci 1998 ; 19: 161-170.
19. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960 ; 23: 56-62.
20. Vickrey BG, Hays RD, Harooni R., Myers LW, Ellison GW A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995 ; 4: 187-206.
21. Fisk JD, Ritvo PG, Ross L., Haase DA, Marrie TJ, Schlech WF Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994 ; 18: S79 - S83.
22. Granger CV Assessment of functional status: a model for multiple sclerosis. Acta Neurol Scand 1981 ; 64 (Suppl 87). 40-47.
23. Colombo L., Sartori G., Brivio C. La stima del quoziente intellettivo tramite lapplicazione del TIB (test di intelligenza breve). G Ital Psicol 2002 ; 3: 613-637.
24. Kaufman AS, Wang JJ Gender, race, and education differences on the K-Bit at ages 4 to 90 years. J Psychoeducat Assess 1992 ; 10: 219-229.
25. Amato MP, Portaccio E., Goretti B., et al. The Raos Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. Mult Scler 2006 ; 12: 787-793.
26. Camp SJ, Stevenson VL, Thompson AJ, et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain 1999 ; 122: 1341-1348.
27. Jenkinson C., Stradling J., Petersen S. Comparison of three measures of quality of life outcome in the evaluation of continuous positive airways pressure therapy for sleep apnoea. J Sleep Res 1997 ; 6: 199-204.
28. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001 ; 56: 1628-1636.
29. Rieckmann P., OConnor P., Francis GS, Wetherill G., Alteri E. Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis. Drug Saf 2004 ; 27: 745-756.
30. Denney DR, Lynch SG, Parmenter BA A 3-year longitudinal study of cognitive impairment in patients with primary progressive multiple sclerosis: speed matters. J Neurol Sci 2008 ; 267: 129-136.
31. Kujala P., Portin R., Ruutiainen J. The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain 1997 ; 120: 289-297.
32. Amato MP, Ponziani G., Pracucci G., Bracco L., Siracusa G., Amaducci L. Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol 1995 ; 52: 168-172.
33. Jennekens-Schinkel A., Laboyrie PM, Lanser JB, van der Velde EA Cognition in patients with multiple sclerosis after four years. J Neurol Sci 1990 ; 99: 229-247.
34. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000 ; 48: 885-892.
35. Benson K., Hartz AJ A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000 ; 342: 1878-1886.
36. Trojano M. Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis? Neurology 2007 ; 69: 1478-1479.
37. Schwid SR, Goodman AD, Weinstein A., McDermott MP, Johnson KP Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. J Neurol Sci 2007 ; 255: 57-63.
38. Pliskin NH, Hamer DP, Goldstein DS, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996 ; 47: 1463-1468.
39. Flechter S., Vardi J., Finkelstein Y., Pollak L. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study. Isr Med Assoc J 2007 ; 9: 457-459.
40. Weinstein A., Schwid SI, Schiffer RB, McDermott MP, Giang DW, Goodman AD Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999 ; 56: 319-324.
41. Caggiula M., Batocchi AP, Frisullo G., et al. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clin Immunol 2006 ; 118: 77-82.
42. Biernacki K., Antel JP, Blain M., Narayanan S., Arnold DL, Prat A. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch Neurol 2005 ; 62: 563-568.
43. Amato MP, Portaccio E., Zipoli V. Are there protective treatments for cognitive decline in MS? J Neurol Sci 2006 ; 245: 183-186.
44. Christodoulou C., Melville P., Scherl WF, MacAllister WS, Elkins LE, Krupp LB Effects of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci 2006 ; 245: 127-136.
45. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000 ; 343: 898-904.
46. Kuhlmann T., Lingfeld G., Bitsch A., Schuchardt J., Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002 ; 125: 2202-2212.
47. Kappos L., Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007 ; 370: 389-397.
48. Filippi M., Rovaris M., Inglese M., et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet 2004 ; 364: 1489-1496.